Category Archives: Psoriasis

My Natural Hair! Psoriasis talk! ACV Rinse talk!
Just wanted to share what #39;s under the wig with you guys!!! A little bit on what I use and some details on my scalp condition! XOXO.

By: TheeBrittanyShow

Follow this link:
My Natural Hair! Psoriasis talk! ACV Rinse talk! - Video

Dermatology Pt 2 - Mouth ulcers, Warts, Psoriasis, Inertigo Remedies
Dermatology Pt 2. Learn the various home and natural remedies for treatment of Mouth ulcers, Warts, Psoriasis, Inertigo Remedies.

By: samkadya

Here is the original post:
Dermatology Pt 2 - Mouth ulcers, Warts, Psoriasis, Inertigo Remedies - Video

How to Psoriasis Treatment - Skin Disorder
Psoriasis treatment - Skin Disorders - Eczema - Acne http://www.mento-neeminternational.com A skin disorder is a disorder or disease that affects the skin. T...

By: MentoNeem

Link:
How to Psoriasis Treatment - Skin Disorder - Video

Scalp Psoriasis Treatment
http://tinyurl.com/d8yrgqk More info here! Scalp Psoriasis Treatment How To Permanently Eliminate Psoriasis? Psoriasis symptoms like scalp psoriasis, Eczema,...

By: Scalppsoriasis2

Continue reading here:
Scalp Psoriasis Treatment - Video

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013" report to their offering.

Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris). Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Plaque Psoriasis (Psoriasis Vulgaris).

- A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

The rest is here:
Research and Markets: Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013

Editor's Choice Main Category: Eczema / Psoriasis Also Included In: Hypertension Article Date: 11 Apr 2013 - 0:00 PDT

Current ratings for: Psoriasis Increases Risk Of High Blood Pressure

4.5 (2 votes)

Psoriasis is a critical, inflammatory, noncommunicable disease that affects over 125 million people internationally. People with psoriasis are known to have an elevated risk of developing grave co-morbid conditions, such as:

Lars Ettarp, President of IFPA, commented:

There are studies indicating that treating psoriasis early and efficiently lowers the risk for co-morbid conditions, such as high blood pressure, and this needs to be taken into account when developing a treatment regimen for an individual with psoriasis."

This year's World Health Day aimed to highlight the global health crisis of high blood pressure and how it can be avoided, treated, and controlled. Issues associated with high blood pressure cause over 9 million deaths annually around the world and affect more than one in three adults, according to the WHO.

High blood pressure is also linked to several behavioral risk factors, including:

A separate study from 2009, conducted by the Brigham and Women's Hospital, Harvard Medical School and Harvard School of Public Health, in Boston, suggested that psoriasis is associated with an increased risk of diabetes and high blood pressure in women. They said more studies need to be carried out to determine whether treating psoriasis might also reduce the risk of diabetes and hypertension.

In other research released last year, psoriasis patients were encouraged to be aware of their condition and its link to other serious illnesses. These patients are at an increased risk for insulin resistance, obesity, cardiovascular diseases, and abnormal levels of cholesterol.

Read more here:
Psoriasis Increases Risk Of High Blood Pressure

How I cured my psoriasis (part 2)
http://highonhealth.org This video from Ally explores more about her struggle and solution with psoriasis. She has gone through such a deep journey with it.....

By: highonhealth

See the original post:
How I cured my psoriasis (part 2) - Video

WASHINGTON--(BUSINESS WIRE)--

The International Federation of Psoriasis Associations, IFPA, commends the World Health Organization for raising awareness of the risks associated with high blood pressure and calls for healthcare professionals to regularly scan for the condition in patients with psoriasis.

Psoriasis is a serious, inflammatory, noncommunicable disease, affecting more than 125 million people all over the world. People with psoriasis are known to carry an increased risk of developing severe co-morbid conditions such as diabetes and psoriatic arthritis, as well as depression and even suicidal ideation[i]. A number of studies also show that psoriasis is associated with greater prevalence of hypertension[ii], one of the most important risk factors for cardiovascular disease[iii].

Healthcare professionals need to recognize the elevated risk that people with psoriasis carry for developing high blood pressure, and include regular tests for hypertension and other known risk factors of cardiovascular disease for this patient group, says Lars Ettarp, President of IFPA. There are studies indicating that treating psoriasis early and efficiently lowers the risk for co-morbid conditions, such as high blood pressure, and this needs to be taken into account when developing a treatment regimen for an individual with psoriasis.

This years World Health Day focused on the global health crisis of high blood pressure and how it can be prevented, treated and controlled. According to the WHO, complications of high blood pressure account for more than 9 million deaths worldwide per year and affects more than one in three adults[iv]. High blood pressure has been connected to a number of behavioral risk factors, such as high salt intake, excessive use of alcohol and physical inactivity.[v]

However, it must also be acknowledged that there are other markers for hypertension and cardiovascular disease, namely genetic conditions and inflammatory diseases such as psoriasis; conditions that cannot be prevented, but in most cases can, and need to, be treated in order to minimize the risks of further complications.

The International Federation of Psoriasis Associations (IFPA)

The International Federation of Psoriasis Associations (IFPA) is the non-profit umbrella organization for the majority of psoriasis associations from around the world. Today IFPA has 51 member associations covering all regions of the world. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of the more than 125 million people who live with psoriasis and/or psoriatic arthritis. IFPA is actively campaigning for recognition of psoriasis as a serious, noncommunicable disease by the World Health Organizations member states.

You can read more about IFPA, our members and our activities on our website http://www.ifpa-pso.org.

----------------------------------------------------------------------

Read more:
International Federation of Psoriasis Associations: People with Psoriasis have Increased Risk of High Blood Pressure

Targeting psoriasis, rheumatoid arthritis, and other immune diseases has created some massive markets over the last decade. How massive? The market was sized up at an estimated $72.2 billion in 2010, according to BCC Research -- and growth isn't slowing any time soon. That's good news for patients, too. The pharmaceutical industry's fascination with an improved understanding of biologics has led to dozens of drugs that treat the underlying causes of diseases, rather than small molecules of years past that only treated symptoms.

Few companies haven't joined the rush to develop biologics and novel small molecule classes to treat immune diseases. While some companies got a big head start over the field, next-generation therapies are being developed in pipelines across the industry. Merck (NYSE: MRK) is one company looking to capitalize on the trend and will shortly begin phase 3 trials on its leading psoriasis biologic therapy candidate. Going by the catchy pipeline name of MK-3222, the drug has huge potential if it ever receives approval from the Food and Drug Administration, or FDA.

About that competition I mentioned...Older therapies aren't exactly losing their grasp on the markets they took by storm just yet. A quick look at 2012 sales data from the first three biologics approved that work by inhibiting the TNF-alpha protein -- integral to immune system communication -- shows exactly that.

Company

Drug

2012 Sales

Johnson & Johnson (NYSE: JNJ)

Remicade

$6,139 million

Amgen (NASDAQ: AMGN)

Read this article:
Can Merck Field a Psoriasis Blockbuster?

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/svtpzt/severe_psoriasis) has announced the addition of the "Severe Psoriasis - Pipeline Review, H1 2013" report to their offering.

Global Markets Direct's, 'Severe Psoriasis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Severe Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Severe Psoriasis.

Scope

- A snapshot of the global therapeutic scenario for Severe Psoriasis.

- A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Severe Psoriasis pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

Read the original here:
Research and Markets: Severe Psoriasis - Pipeline Review, H1 2013